Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Drug Profile

Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Alternative Names: BMS-247616; CDHP/potassium-oxonate/tegafur; CIDU/potassium-oxonate/tegafur; Oteracil/tegafur/gimeracil; Potassium-oxonate/tegafur/CDHP; Potassium-oxonate/tegafur/CIDU; S-1; Tegafur/CDHP/potassium-oxonate; Tegafur/CIDU/potassium-oxonate; Tegafur/gimeracil/oteracil; Tegafur/potassium-oxonate/CDHP; Tegafur/potassium-oxonate/CIDU; Teysuno; TS-1; TS-ONE

Latest Information Update: 04 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Helsinki University Central Hospital; Nordic Group; Shandong New age Pharmaceutical; Taiho Pharmaceutical; TTY Biopharm
  • Class Antineoplastics; Pyridines; Pyrimidinones; Small molecules; Triazines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase III Cervical cancer; Liver cancer; Oesophageal cancer; Uterine cancer
  • Phase II Gastrointestinal cancer; Renal cancer
  • No development reported Prostate cancer

Most Recent Events

  • 07 Jan 2019 The Tokyo Cooperative Oncology Group completes a phase II trial in Rectal cancer (Late stage disease) in Japan (PO) (UMIN000011115)
  • 01 Dec 2018 Taiho Pharmaceutical completes a phase III trial in Gastric cancer and Oesophageal cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in China (PO) (NCT01824459)
  • 27 Aug 2018 Nordic Group terminates a phase II trial in Gastrointestinal cancer (Combination therapy, Metastatic disease, Late-stage disease, In adults, In the elderly) in Finland, Denmark (PO) (EudraCT2013-003976-11) (NCT02216149)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top